Microbiota and metabolic diseases

Endocrine

Volumn 61, Issue 3, 2018, Pages 357-371

  Pascale, Alessia ^a   Marchesi, Nicoletta ^a   Marelli, Cristina ^a   Coppola, Adriana ^b   Luzi, Livio ^c,d   Govoni, Stefano ^a   Giustina, Andrea ^e   Gazzaruso, Carmine ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b Diabetes and endocrine and metabolic diseases Unit and the Centre for Applied Clinical Research (CeRCA) Clinical Institute Beato Matteo (Hospital Group San Donato)   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular disease; Diabetes; Metabolic syndrome; Microbiome; Microbiota; Obesity

Indexed keywords

ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT;

ACTINOBACTERIA; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; BACTERIAL GENETIC PHENOMENA AND FUNCTIONS; BACTEROIDES OVATUS; BACTEROIDETES; BIOLOGICAL FUNCTIONS; CLOSTRIDIUM DIFFICILE INFECTION; COLD; CYANOBACTERIUM; DYSBIOSIS; ENDOTHELIAL DYSFUNCTION; ESCHERICHIA COLI; EUBIOSIS; FIRMICUTES; FUSOBACTERIA; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTESTINE FLORA; LACTOBACILLUS CASEI; LACTOCOCCUS LACTIS; MEDITERRANEAN DIET; METABOLIC DISORDER; MICROBIAL ACTIVITY; MICROFLORA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEOBACTERIA; REVIEW; SPIROCHETE; THROMBOSIS; TRANSPLANTATION; VERRUCOMICROBIA; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISEASES; MICROBIOTA;

EID: 85049350449     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-018-1605-5     Document Type: Review

References (134)

1. R. Sender, S. Fuchs, R. Milo, Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016). 10.1371/journal.pbio.1002533
2. C. Palmer, E.M. Bik, D.B. DiGiulio, D.A. Relman, P.O. Brown, Development of the human infant intestinal microbiota. PLoS Biol. 5, 1556–1573 (2007). 10.1371/journal.pbio.0050177
3. A. Pingitore, E.S. Chambers, T. Hill, I.R. Maldonado, B. Liu, G. Bewick, D.J. Morrison, T. Preston, G.A. Wallis, C. Tedford, R. Castañera González, G.C. Huang, P. Choudhary, G. Frost, S.J. Persaud, The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes. Metab. 19, 257–265 (2017). 10.1111/dom.12811
4. F. Bäckhed, J. Roswall, Y. Peng, Q. Feng, H. Jia, P. Kovatcheva-Datchary, Y. Li, Y. Xia, H. Xie, H. Zhong, M.T. Khan, J. Zhang, J. Li, L. Xiao, J. Al-Aama, D. Zhang, Y.S. Lee, D. Kotowska, C. Colding, V. Tremaroli, Y. Yin, S. Bergman, X. Xu, L. Madsen, K. Kristiansen, J. Dahlgren, J. Wang, W. Jun, Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690–703 (2015). 10.1016/j.chom.2015.04.004
5. B.S. Ramakrishna, The normal bacterial flora of the human intestine and its regulation. J. Clin. Gastroenterol. 41, S2–S6 (2007)
6. F. Bäckhed, C.M. Fraser, Y. Ringel, M.E. Sanders, R.B. Sartor, P.M. Sherman, J. Versalovic, V. Young, B.B. Finlay, Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12, 611–622 (2012). 10.1016/j.chom.2012.10.012
7. Human Microbiome Project C., A framework for human microbiome research. Nature 486, 215–221 (2012). 10.1038/nature11209
8. E.A. Grice, J.A. Segre, The human microbiome: our second genome. Annu. Rev. Genom. Hum. Genet. 13, 151–170 (2012). 10.1146/annurev-genom-090711-163814
9. D.A. Hill, D. Artis, Intestinal bacteria and the regulation of immune cell homeostasis. Annu. Rev. Immunol. 28, 623–667 (2010). 10.1146/annurev-immunol-030409-101330
10. C. Mueller, A.J. Macpherson, Layers of mutualism with commensal bacteria protect us from intestinal inflammation. Gut 55, 276–284 (2006)
11. F. Guarner, J.-R. Malagelada, Gut flora in health and disease. Lancet 361, 512–519 (2003). 10.1016/S0140-6736(03)12489-0
12. I. Rowland, G. Gibson, A. Heinken, K. Scott, J. Swann, I. Thiele, K. Tuohy, Gut microbiota functions: metabolism of nutrients and other food components. Eur. J. Nutr. 57(1), 1–24 (2017). 10.1007/s00394-017-1445-8
13. L. Capurso, Il Microbiota intestinale. Recent. Prog. Med. 107, 257–266 (2016)
14. E.F. Enright, C.G.M. Gahan, S.A. Joyce, B.T. Griffin, The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382 (2016)
15. D.R. Donohoe, N. Garge, X. Zhang, W. Sun, T.M. O’Connell, M.K. Bunger, S.J. Bultman, The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517–526 (2011). 10.1016/j.cmet.2011.02.018
16. N. Kobyliak, O. Virchenko, T. Falalyeyeva, Pathophysiological role of host microbiota in the development of obesity. Nutr. J. 15, 1–12 (2016). 10.1186/s12937-016-0166-9
17. Y.E. Borre, G.W. O’Keeffe, G. Clarke, C. Stanton, T.G. Dinan, J.F. Cryan, Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol. Med. 20, 509–518 (2014). 10.1016/j.molmed.2014.05.002
18. D.J. Morrison, T. Preston, Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7, 189–200 (2016). 10.1080/19490976.2015.1134082
19. G. den Besten, K. van Eunen, A.K. Groen, K. Venema, D.-J. Reijngoud, B.M. Bakker, The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013). 10.1194/jlr.R036012
20. G.T. Macfarlane, G.R. Gibson, J.H. Cummings, Comparison of fermentation reactions in different regions of the human colon. J. Appl. Bacteriol. 72, 57–64 (1992). 10.1111/j.1365-2672.1992.tb04882.x
21. J.G. LeBlanc, F. Chain, R. Martín, L.G. Bermúdez-Humarán, S. Courau, P. Langella, Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb. Cell Fact. 16, 1–10 (2017). 10.1186/s12934-017-0691-z
22. C.K. Chakraborti, New-found link between microbiota and obesity. World J. Gastrointest. Pathophysiol. 6, 110–119 (2015). 10.4291/wjgp.v6.i4.110
23. X. Li, Y. Shimizu, I. Kimura, Gut microbial metabolite short-chain fatty acids and obesity. Biosci. Micro., Food Heal. 36, 135–140 (2017). 10.12938/bmfh.17-010
24. P. Schönfeld, L. Wojtczak, Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J. Lipid Res. 57, 943–954 (2016). 10.1194/jlr.R067629
25. D.N. Cooper, R.J. Martin, N.L. Keim, Does whole grain consumption alter gut microbiota and satiety? Healthc. (Basel, Switz.) 3, 364–392 (2015). 10.3390/healthcare3020364
26. A. Everard, P.D. Cani, Gut microbiota and GLP-1. Rev. Endocr. Metab. Disord. 15, 189–196 (2014)
27. G. Frost, M.L. Sleeth, M. Sahuri-Arisoylu, B. Lizarbe, S. Cerdan, L. Brody, J. Anastasovska, S. Ghourab, M. Hankir, S. Zhang, D. Carling, J.R. Swann, G. Gibson, A. Viardot, D. Morrison, E.L. Thomas, J.D. Bell, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014). 10.1038/ncomms4611
28. L.E.M. Willemsen, M.A. Koetsier, S.J.H. van Deventer, E.A.F. van Tol, Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 52, 1442–1447 (2003)
29. F.J. Cousin, S. Jouan-Lanhouet, N. Theret, C. Brenner, E. Jouan, G. Le Moigne-Muller, M.-T. Dimanche-Boitrel, G. Jan, The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget 7, 7161–7178 (2016). 10.18632/oncotarget.6881
30. J. Ni, G.D. Wu, L. Albenberg, V.T. Tomov, Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 14, 573–584 (2017)
31. H.J. Flint, E.A. Bayer, Plant cell wall breakdown by anaerobic microorganisms from the mammalian digestive tract. Ann. New Y. Acad. Sci. 1125, 280–288 (2008)
32. P. van den Abbeele, P. Gérard, S. Rabot, A. Bruneau, S. El Aidy, M. Derrien, M. Kleerebezem, E.G. Zoetendal, H. Smidt, W. Verstraete, T. van de Wiele, S. Possemiers, Arabinoxylans and inulin differentially modulate the mucosal and luminal gut microbiota and mucin-degradation in humanized rats. Environ. Microbiol. 13, 2667–2680 (2011). 10.1111/j.1462-2920.2011.02533.x
33. A.L. McOrist, R.B. Miller, A.R. Bird, J.B. Keogh, M. Noakes, D.L. Topping, M.A. Conlon, Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. J. Nutr. 141, 883–889 (2011). 10.3945/jn.110.128504
34. C. Grootaert, P. Van Den Abbeele, M. Marzorati, W.F. Broekaert, C.M. Courtin, J.A. Delcour, W. Verstraete, T. Van De Wiele, Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol. Ecol. 69, 231–242 (2009). 10.1111/j.1574-6941.2009.00712.x
35. M. Begley, C. Hill, C.G.M. Gahan, Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72, 1729–1738 (2006). 10.1128/AEM.72.3.1729-1738.2006
36. WHO | Obesity and overweight. (WHO, Geneva, Switzerland, 2018)
37. K. Ball, G. Mishra, D. Crawford, Which aspects of socioeconomic status are related to obesity among men and women? Int. J. Obes. Relat. Metab. Disord. 26, 559–565 (2002). 10.1038/sj.ijo.0801960
38. J.F. Rawls, M.A. Mahowald, R.E. Ley, J.I. Gordon, Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell 127, 423–433 (2018). 10.1016/j.cell.2006.08.043
39. R. Ley, P. Turnbaugh, S. Klein, J. Gordon, Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006). 10.1038/nature4441021a
40. M.A. Hildebrandt, C. Hoffman, S.A. Sherrill-Mix, S.A. Keilbaugh, M. Hamady, Y.-Y. Chen, R. Knight, R.S. Ahima, F. Bushman, G.D. Wu, High fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1712–1716 (2009). 10.1053/j.gastro.2009.08.042
41. P.J. Turnbaugh, F. Bäckhed, L. Fulton, J.I. Gordon, Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–223 (2008). 10.1016/j.chom.2008.02.015
42. M.A. Conlon, A.R. Bird, The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7, 17–44 (2015). 10.3390/nu7010017
43. J. Hamzelou, Antibiotic overuse may promote obesity. New Sci. 213, 8–9 (2012). 10.1016/S0262-4079(12)60797-0
44. L. Trasande, J. Blustein, M. Liu, E. Corwin, L.M. Cox, M.J. Blaser, Infant antibiotic exposures and early-life body mass. Int. J. Obes. (Lond.). 37, 16–23 (2013). 10.1038/ijo.2012.132
45. L. Dethlefsen, D.A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. U.S.A. 108, Suppl, 4554–4561 (2011). 10.1073/pnas.1000087107
46. P. Vangay, T. Ward, J.S. Gerber, D. Knights, Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 17, 553–564 (2015). 10.1016/J.CHOM.2015.04.006
47. F. Bäckhed, H. Ding, T. Wang, L.V. Hooper, G.Y. Koh, A. Nagy, C.F. Semenkovich, J.I. Gordon, The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. U.S.A. 101, 15718–15723 (2004). 10.1073/pnas.0407076101
48. P.J. Turnbaugh, R.E. Ley, M.A. Mahowald, V. Magrini, E.R. Mardis, J.I. Gordon, An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006). 10.1038/nature05414
49. A.P. Liou, M. Paziuk, J.M. Luevano, S. Machineni, P.J. Turnbaugh, L.M. Kaplan, Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5, 178ra41 (2013). 10.1126/scitranslmed.3005687
50. S. Kersten, S. Mandard, N.S. Tan, P. Escher, D. Metzger, P. Chambon, F.J. Gonzalez, B. Desvergne, W. Wahli, Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275, 28488–28493 (2000). 10.1074/jbc.M004029200
51. E.M. Cushing, X. Chi, K.L. Sylvers, S.K. Shetty, M.J. Potthoff, B.S.J. Davies, Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol. Metab. 6, 809–818 (2017). 10.1016/j.molmet.2017.06.007
52. F. Bäckhed, J.K. Manchester, C.F. Semenkovich, J.I. Gordon, Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. U.S.A. 104, 979–984 (2007). 10.1073/pnas.0605374104
53. N.E. Boutagy, R.P. McMillan, M.I. Frisard, M.W. Hulver, Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie 124, 11–20 (2016). 10.1016/j.biochi.2015.06.020
54. H. Ghanim, S. Abuaysheh, C.L. Sia, K. Korzeniewski, A. Chaudhuri, J.M. Fernandez-Real, P. Dandona, Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: Implications for insulin resistance. Diabetes Care 32, 2281–2287 (2009). 10.2337/dc09-0979
55. P.D. Cani, J. Amar, M.A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A.M. Neyrinck, F. Fava, K.M. Tuohy, C. Chabo, A. Waget, E. Delmée, B. Cousin, T. Sulpice, B. Chamontin, J. Ferrières, J.F. Tanti, G.R. Gibson, L. Casteilla, N.M. Delzenne, M.C. Alessi, R. Burcelin, Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007). 10.2337/db06-1491
56. M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell. Biol. 13, 1016–1023 (2011). 10.1038/ncb2329
57. E. Le Poul, C. Loison, S. Struyf, J.-Y. Springael, V. Lannoy, M.-E. Decobecq, S. Brezillon, V. Dupriez, G. Vassart, J. Van Damme, M. Parmentier, M. Detheux, Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481–25489 (2003). 10.1074/jbc.M301403200
58. A.J. Brown, S.M. Goldsworthy, A.A. Barnes, M.M. Eilert, L. Tcheang, D. Daniels, A.I. Muir, M.J. Wigglesworth, I. Kinghorn, N.J. Fraser, N.B. Pike, J.C. Strum, K.M. Steplewski, P.R. Murdock, J.C. Holder, F.H. Marshall, P.G. Szekeres, S. Wilson, D.M. Ignar, S.M. Foord, A. Wise, S.J. Dowell, The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312–11319 (2003). 10.1074/jbc.M211609200
59. B.S. Samuel, A. Shaito, T. Motoike, F.E. Rey, F. Backhed, J.K. Manchester, R.E. Hammer, S.C. Williams, J. Crowley, M. Yanagisawa, J.I. Gordon, Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. 105, 16767–16772 (2008)
60. M. Bjursell, T. Admyre, M. Göransson, A.E. Marley, D.M. Smith, J. Oscarsson, M. Bohlooly-Y, Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am. J. Physiol. Metab. 300, E211–E220 (2010). 10.1152/ajpendo.00229.2010
61. V.K. Ridaura, J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau, N.W. Griffin, V. Lombard, B. Henrissat, J.R. Bain, M.J. Muehlbauer, O. Ilkayeva, C.F. Semenkovich, K. Funai, D.K. Hayashi, B.J. Lyle, M.C. Martini, L.K. Ursell, J.C. Clemente, W. Van Treuren, W.A. Walters, R. Knight, C.B. Newgard, A.C. Heath, J.I. Gordon, Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013). 10.1126/science.1241214
62. N.-R. Shin, J.-C. Lee, H.-Y. Lee, M.-S. Kim, T.W. Whon, M.-S. Lee, J.-W. Bae, An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014). 10.1136/gutjnl-2012-303839
63. American Diabetes Association A.D., Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62–S69 (2010). 10.2337/dc10-S062
64. WHO Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. (WHO, Geneva, Switzerland, 2013)
65. F. Navab-Moghadam, M. Sedighi, M.E. Khamseh, F. Alaei-Shahmiri, M. Talebi, S. Razavi, N. Amirmozafari, The association of type II diabetes with gut microbiota composition. Microb. Pathog. 110, 630–636 (2017). 10.1016/j.micpath.2017.07.034
66. H. Wu, E. Esteve, V. Tremaroli, M.T. Khan, R. Caesar, L. Mannerås-Holm, M. Ståhlman, L.M. Olsson, M. Serino, M. Planas-Fèlix, G. Xifra, J.M. Mercader, D. Torrents, R. Burcelin, W. Ricart, R. Perkins, J.M. Fernàndez-Real, F. Bäckhed, Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017). 10.1038/nm.4345
67. M.C. De Goffau, S. Fuentes, B. Van Den Bogert, H. Honkanen, W.M. De Vos, G.W. Welling, H. Hyöty, H.J.M. Harmsen, Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 57, 1569–1577 (2014). 10.1007/s00125-014-3274-0
68. S. Hasan, V. Aho, P. Pereira, L. Paulin, S.B. Koivusalo, P. Auvinen, J.G. Eriksson, Gut microbiome in gestational diabetes: a cross-sectional study of mothers and offspring 5 years postpartum. Acta Obstet. Gynecol. Scand. 97, 38–46 (2018). 10.1111/aogs.13252
69. N. Larsen, F.K. Vogensen, F.W.J. Van Den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen, W.A. Al-Soud, S.J. Sørensen, L.H. Hansen, M. Jakobsen, Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5, e9085 (2010). 10.1371/journal.pone.0009085
70. D. Ríos-Covián, P. Ruas-Madiedo, A. Margolles, M. Gueimonde, C.G. de Los Reyes-Gavilán, N. Salazar, Intestinal short chain fatty acids and their link with diet and human health. Front. Microbiol. 7, 185 (2016). 10.3389/fmicb.2016.00185
71. Z. Gao, J. Yin, J. Zhang, R.E. Ward, R.J. Martin, M. Lefevre, W.T. Cefalu, J. Ye, Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009). 10.2337/db08-1637
72. H.V. Lin, A. Frassetto, E.J. Kowalik, A.R. Nawrocki, M.M. Lu, J.R. Kosinski, J.A. Hubert, D. Szeto, X. Yao, G. Forrest, D.J. Marsh, Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7, e35240 (2012). 10.1371/journal.pone.0035240
73. R.J. Perry, L. Peng, N.A. Barry, G.W. Cline, D. Zhang, R.L. Cardone, K.F. Petersen, R.G. Kibbey, A.L. Goodman, G.I. Shulman, Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016). 10.1038/nature18309
74. S. Devaraj, P. Hemarajata, J. Versalovic, The human gut microbiome and body metabolism: Implications for obesity and diabetes. Clin. Chem. 59, 617–628 (2013)
75. M.A.R. Vinolo, H.G. Rodrigues, R.T. Nachbar, R. Curi, Regulation of inflammation by short chain fatty acids. Nutrients 3, 858–876 (2011)
76. A. Vrieze, E. Van Nood, F. Holleman, J. Salojärvi, R.S. Kootte, J.F.W.M. Bartelsman, G.M. Dallinga-Thie, M.T. Ackermans, M.J. Serlie, R. Oozeer, M. Derrien, A. Druesne, J.E.T. Van Hylckama Vlieg, V.W. Bloks, A.K. Groen, H.G.H.J. Heilig, E.G. Zoetendal, E.S. Stroes, W.M. De Vos, J.B.L. Hoekstra, M. Nieuwdorp, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–6.e7 (2012). 10.1053/j.gastro.2012.06.031
77. P.D. Cani, N.M. Delzenne, The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 15, 1546–1558 (2009). 10.2174/138161209788168164
78. P.D. Cani, S. Possemiers, T. Van De Wiele, Y. Guiot, A. Everard, O. Rottier, L. Geurts, D. Naslain, A. Neyrinck, D.M. Lambert, G.G. Muccioli, N.M. Delzenne, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103 (2009). 10.1136/gut.2008.165886
79. S. Hædersdal, A. Lund, F.K. Knop, T. Vilsbøll, The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin. Proc. 93, 217–239 (2018). 10.1016/j.mayocp.2017.12.003
80. C.S. Marathe, C.K. Rayner, K.L. Jones, M. Horowitz, Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 36, 1396–1405 (2013). 10.2337/dc12-1609
81. G.S. Papaetis, Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J. Diabetes 5, 817–834 (2014). 10.4239/wjd.v5.i6.817
82. J. Bland, Intestinal microbiome, akkermansia muciniphila, and medical nutrition therapy. Integr. Med. (Encinitas). 15, 14–16 (2016). 10.1136/gutjnl-2015-310904
83. K. Forslund, F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa, E. Prifti, S. Vieira-Silva, V. Gudmundsdottir, H. Krogh Pedersen, M. Arumugam, K. Kristiansen, A. Yvonne Voigt, H. Vestergaard, R. Hercog, P. Igor Costea, J. Roat Kultima, J. Li, T. Jørgensen, F. Levenez, J. Dore, H. Bjørn Nielsen, S. Brunak, J. Raes, T. Hansen, J. Wang, S. Dusko Ehrlich, P. Bork, O. Pedersen, Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015). 10.1038/nature15766
84. N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C. Suarez-Cuervo, Z. Berger, Y. Chu, E. Iyoha, J.B. Segal, S. Bolen, Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016)
85. D. Kopelman, I. Caterson, J. Michael, W. HD, Clinical obesity in adults and children. (2009)
86. K.M. Levri, E. Slaymaker, A. Last, J. Yeh, J. Ference, F. D’Amico, S.A. Wilson, Metformin as treatment for overweight and obese adults: A systematic review. Ann. Fam. Med. 3, 457–461 (2005)
87. M.P. van der Aa, M.A.J. Elst, E.M.W. van de Garde, E.G.A.H. van Mil, C.A.J. Knibbe, M.M.J. van der Vorst, Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr. Diabetes 6, e228 (2016). 10.1038/nutd.2016.37
88. U. Uusitalo, X. Liu, J. Yang, C.A. Aronsson, S. Hummel, M. Butterworth, Å. Lernmark, M. Rewers, W. Hagopian, J.-X. She, O. Simell, J. Toppari, A.G. Ziegler, B. Akolkar, J. Krischer, J.M. Norris, S.M. Virtanen; TEDDY Study Group, Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 33612, 1–9 (2015). 10.1001/jamapediatrics.2015.2757
89. W.-H. Lee, P.-C. Hsu, C.-Y. Chu, H.-M. Su, C.-S. Lee, H.-W. Yen, T.-H. Lin, W.-C. Voon, W.-T. Lai, S.-H. Sheu, Cardiovascular events in patients with atherothrombotic disease: a population-based longitudinal study in Taiwan. PLoS. One. 9, e92577 (2014). 10.1371/journal.pone.0092577
90. C. Gazzaruso, S.B. Solerte, E. De Amici, M. Mancini, A. Pujia, P. Fratino, A. Giustina, A. Garzaniti, Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. Am. J. Cardiol. 97, 236–239 (2006). 10.1016/j.amjcard.2005.07.133
91. C. Gazzaruso, A. Coppola, A. Giustina, Erectile dysfunction and coronary artery disease in patients with diabetes. Curr. Diabetes Rev. 7, 143–147 (2011). 10.2174/157339911794940693
92. G.S. Crowther, M.H. Wilcox, Antibiotic therapy and Clostridium difficile infection -primum non nocere - first do no harm. Infect. Drug Resist. 8, 333–337 (2015). 10.2147/IDR.S87224
93. W.H.W. Tang, Z. Wang, D.J. Kennedy, Y. Wu, J.A. Buffa, B. Agatisa-Boyle, X.S. Li, B.S. Levison, S.L. Hazen, Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448–455 (2015). 10.1161/CIRCRESAHA.116.305360
94. R.A. Koeth, Z. Wang, B.S. Levison, J.A. Buffa, E. Org, B.T. Sheehy, E.B. Britt, X. Fu, Y. Wu, L. Li, J.D. Smith, J.A. Didonato, J. Chen, H. Li, G.D. Wu, J.D. Lewis, M. Warrier, J.M. Brown, R.M. Krauss, W.H.W. Tang, F.D. Bushman, A.J. Lusis, S.L. Hazen, Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013). 10.1038/nm.3145
95. R.A. Koeth, B.S. Levison, M.K. Culley, J.A. Buffa, Z. Wang, J.C. Gregory, E. Org, Y. Wu, L. Li, J.D. Smith, W.H.W. Tang, J.A. Didonato, A.J. Lusis, S.L. Hazen, γ-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell. Metab. 20, 799–812 (2014). 10.1016/j.cmet.2014.10.006
96. W.H.W. Tang, Z. Wang, Y. Fan, B. Levison, J.E. Hazen, L.M. Donahue, Y. Wu, S.L. Hazen, Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J. Am. Coll. Cardiol. 64, 1908–1914 (2014)
97. W.P. Fay, Homocysteine and thrombosis: Guilt by association? Blood 119, 2977–2978 (2012)
98. R. Ostan, M.C. Béné, L. Spazzafumo, A. Pinto, L.M. Donini, F. Pryen, Z. Charrouf, L. Valentini, H. Lochs, I. Bourdel-Marchasson, C. Blanc-Bisson, F. Buccolini, P. Brigidi, C. Franceschi, P.A. d’Alessio, Impact of diet and nutraceutical supplementation on inflammation in elderly people. Results from the RISTOMED study, an open-label randomized control trial. Clin. Nutr. 35, 812–818 (2016). 10.1016/j.clnu.2015.06.010
99. J.L. Griffin, X. Wang, E. Stanley, Does Our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics. Circ. Cardiovasc Genet. 8, 187–191 (2015)
100. J. Joseph, J. Loscalzo, Nutri(meta)genetics and cardiovascular disease: novel concepts in the interaction of diet and genomic variation. Curr. Atherosler Rep. 17, 505 (2015)
101. W.H.W. Tang, S.L. Hazen, The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest. 124, 4204–4211 (2014). 10.1172/JCI72331
102. T. Yang, M.M. Santisteban, V. Rodriguez, E. Li, N. Ahmari, J.M. Carvajal, M. Zadeh, M. Gong, Y. Qi, J. Zubcevic, B. Sahay, C.J. Pepine, M.K. Raizada, M. Mohamadzadeh, Gut dysbiosis is linked to hypertension. Hypertension 65, 1331–1340 (2015). 10.1161/HYPERTENSIONAHA.115.05315
103. X.T. Gan, G. Ettinger, C.X. Huang, J.P. Burton, J.V. Haist, V. Rajapurohitam, J.E. Sidaway, G. Martin, G.B. Gloor, J.R. Swann, G. Reid, M. Karmazyn, Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ. Hear. Fail. 7, 491–499 (2014). 10.1161/CIRCHEARTFAILURE.113.000978
104. C.S. Hampe, C.L. Roth, Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. Endocrine 58, 207–227 (2017). 10.1007/s12020-017-1433-z
105. M.H. Floch, Probiotics and prebiotics. Gastroenterol. Hepatol. (N. Y) 10, 680–681 (2014)
106. M.C. Dao, A. Everard, J. Aron-Wisnewsky, N. Sokolovska, E. Prifti, E.O. Verger, B.D. Kayser, F. Levenez, J. Chilloux, L. Hoyles, M.-E. Dumas, S.W. Rizkalla, J. Doré, P.D. Cani, K. Clément, Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436 (2016)
107. C. Chevalier, O. Stojanović, D.J. Colin, N. Suarez-Zamorano, V. Tarallo, C. Veyrat-Durebex, D. Rigo, S. Fabbiano, A. Stevanović, S. Hagemann, X. Montet, Y. Seimbille, N. Zamboni, S. Hapfelmeier, M. Trajkovski, Gut microbiota orchestrates energy homeostasis during cold. Cell 163, 1360–1374 (2015). 10.1016/j.cell.2015.11.004
108. L.J. Cohen, D. Esterhazy, S.-H. Kim, C. Lemetre, R.R. Aguilar, E.A. Gordon, A.J. Pickard, J.R. Cross, A.B. Emiliano, S.M. Han, J. Chu, X. Vila-Farres, J. Kaplitt, A. Rogoz, P.Y. Calle, C. Hunter, J.K. Bitok, S.F. Brady, Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549, 48–53 (2017). 10.1038/nature23874
109. M. Mimee, R.J. Citorik, T.K. Lu, Microbiome therapeutics—Advances and challenges. Adv. Drug. Deliv. Rev. 105, 44–54 (2016)
110. Z.Z.R. Hamady, N. Scott, M.D. Farrar, M. Wadhwa, P. Dilger, T.R. Whitehead, R. Thorpe, K.T. Holland, J.P.A. Lodge, S.R. Carding, Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan 1. Inflamm. Bowel. Dis. 17, 1925–1935 (2011). 10.1002/ibd.21565
111. K. Vandenbroucke, H. De Haard, E. Beirnaert, T. Dreier, M. Lauwereys, L. Huyck, J. Van Huysse, P. Demetter, L. Steidler, E. Remaut, C. Cuvelier, P. Rottiers, Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49–56 (2010). 10.1038/mi.2009.116
112. Z.Z.R. Hamady, N. Scott, M.D. Farrar, J.P.A. Lodge, K.T. Holland, T. Whitehead, S.R. Carding, Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59, 461–469 (2010)
113. J.P. Motta, L.G. Bermúdez-Humarán, C. Deraison, L. Martin, C. Rolland, P. Rousset, J. Boue, G. Dietrich, K. Chapman, P. Kharrat, J.P. Vinel, L. Alric, E. Mas, J.M. Sallenave, P. Langella, N. Vergnolle, Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med. 4, 158ra144 (2012). 10.1126/scitranslmed.3004212
114. G.R. Gibson, H.M. Probert, J.Van Loo, R.A. Rastall, M.B. Roberfroid, Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr. Res. Rev. 17, 259 (2004). 10.1079/NRR200479
115. J. Slavin, Fiber and prebiotics: mechanisms and health benefits. Nutrients 5, 1417–1435 (2013). 10.3390/nu5041417
116. M. De Vrese, J. Schrezenmeir, Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111, 1–66 (2008)
117. B.C. Tungland, D. Meyer, Nondigestible oligo- and polysaccharides (dietary fiber): Their physiology and role in human health and food. Compr. Rev. Food Sci. Food Saf. 1, 90–109 (2002). 10.1111/j.1541-4337.2002.tb00009.x
118. Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, B. Dugar, A.E. Feldstein, E.B. Britt, X. Fu, Y.M. Chung, Y. Wu, P. Schauer, J.D. Smith, H. Allayee, W.H.W. Tang, J.A. Didonato, A.J. Lusis, S.L. Hazen, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–65 (2011). 10.1038/nature09922
119. A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine 53, 18–27 (2016)
120. V. Tosti, B. Bertozzi, L. Fontana, Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. J Gerontol A Biol Sci Med Sci. 73, 318–326 (2018)
121. T.T.B. Nguyen, Y.Y. Jin, H.J. Chung, S.T. Hong, Pharmabiotics as an emerging medication for metabolic syndrome and its related diseases. Molecules 22(10), E1795 (2017)
122. R.E. Ley, D.A. Peterson, J.I. Gordon, Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837–848 (2006). 10.1016/J.CELL.2006.02.017
123. R.E. Ley, F. Bäckhed, P. Turnbaugh, C.A. Lozupone, R.D. Knight, J.I. Gordon, Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. U. S. A. 102, 11070–11075 (2005). 10.1073/pnas.0504978102
124. A.L. Komaroff, The microbiome and risk for obesity and diabetes. JAMA 317, 355 (2017). 10.1001/jama.2016.20099
125. S.K. Mazmanian, J.L. Round, D.L. Kasper, A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008). 10.1038/nature07008
126. L. Wen, R.E. Ley, P.Y. Volchkov, P.B. Stranges, L. Avanesyan, A.C. Stonebraker, C. Hu, F.S. Wong, G.L. Szot, J.A. Bluestone, J.I. Gordon, A.V. Chervonsky, Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109–1113 (2008). 10.1038/nature07336
127. Y.S. Kim, J.A. Milner, Dietary modulation of colon cancer risk. J. Nutr. 137, 2576S–2579S (2007)
128. S.K.P. Lau, P.C.Y. Woo, G.K.S. Woo, A.M.Y. Fung, M.K.M. Wong, K.-M. Chan, D.M.W. Tam, K.-Y. Yuen, Eggerthella hongkongensis sp. nov. and eggerthella sinensis sp. nov., two novel Eggerthella species, account for half of the cases of Eggerthella bacteremia. Diagn. Microbiol. Infect. Dis. 49, 255–263 (2004). 10.1016/j.diagmicrobio.2004.04.012
129. M. Kraatz, R.J. Wallace, L. Svensson, Olsenella umbonata sp. nov., a microaerotolerant anaerobic lactic acid bacterium from the sheep rumen and pig jejunum, and emended descriptions of Olsenella, Olsenella uli and Olsenella profusa. Int. J. Syst. Evol. Microbiol. 61, 795–803 (2011). 10.1099/ijs.0.022954-0
130. S.K. Lau, P.C. Woo, A.M. Fung, K. Chan, G.K. Woo, K. Yuen, Anaerobic, non-sporulating, Gram-positive bacilli bacteraemia characterized by 16S rRNA gene sequencing. J. Med. Microbiol. 53, 1247–1253 (2004). 10.1099/jmm.0.45803-0
131. A. Finamore, M. Palmery, S. Bensehaila, I. Peluso, Antioxidant, immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly Spirulina. Oxid. Med. Cell Longev. 2017, 3247528 (2017). 10.1155/2017/3247528. 1–14
132. D.J. Hampson, T. La, N.D. Phillips, Emergence of Brachyspira species and strains: reinforcing the need for surveillance. Porc. Heal. Manag. 1, 8 (2015). 10.1186/s40813-015-0002-1
133. M.Y. Galperin, New feel for new phyla. Environ. Microbiol. 10, 1927–1933 (2008). 10.1111/j.1462-2920.2008.01699.x
134. M. Yamauchi, P. Lochhead, T. Morikawa, C. Huttenhower, A.T. Chan, E. Giovannucci, C. Fuchs, S. Ogino, Colorectal cancer: a tale of two sides or a continuum? Gut 61, 794–797 (2012). 10.1136/gutjnl-2012-302014